SCLX vs. NVO
SCLX (Scilex Holding Company) and NVO (Novo Nordisk A/S) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 5 years, SCLX returned -49.50%/yr vs 5.23%/yr for NVO. At a 0.08 correlation, their price movements are largely independent.
Performance
SCLX vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SCLX achieves a -6.40% return, which is significantly lower than NVO's -2.22% return.
SCLX
- 1D
- 0.28%
- 1M
- 67.67%
- YTD
- -6.40%
- 6M
- -19.02%
- 1Y
- 115.45%
- 3Y*
- -62.53%
- 5Y*
- -49.50%
- 10Y*
- —
NVO
- 1D
- 0.90%
- 1M
- 7.90%
- YTD
- -2.22%
- 6M
- -5.06%
- 1Y
- -25.68%
- 3Y*
- -12.68%
- 5Y*
- 5.23%
- 10Y*
- 8.53%
SCLX vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
SCLX Scilex Holding Company | -6.40% | -18.25% | -79.10% | -48.87% | -60.26% | 1.93% |
NVO Novo Nordisk A/S | -2.22% | -39.22% | -15.93% | 54.84% | 22.66% | 65.01% |
Correlation
The correlation between SCLX and NVO is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.08 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.08 |
Correlation (All Time) Calculated using the full available price history since Mar 5, 2021 | 0.08 |
The correlation between SCLX and NVO shifts across timeframes, from 0.08 (3 years) to 0.18 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
SCLX:
$78.45M
NVO:
$213.85B
SCLX:
-$35.27
NVO:
DKK 27.42
SCLX:
2.68
NVO:
4.29
SCLX:
$30.25M
NVO:
DKK 327.80B
SCLX:
$18.07M
NVO:
DKK 268.30B
SCLX:
-$352.83M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SCLX vs. NVO — Risk / Return Rank
SCLX
NVO
SCLX vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Scilex Holding Company (SCLX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SCLX | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.43 | ||
| Sortino ratioReturn per unit of downside risk | +2.50 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 0.94 | +0.31 |
| Calmar ratioReturn relative to maximum drawdown | 1.45 | -0.52 | +1.97 |
| Martin ratioReturn relative to average drawdown | 2.11 | -0.83 | +2.94 |
Loading charts...
Drawdowns
SCLX vs. NVO - Drawdown Comparison
The maximum SCLX drawdown since its inception was -99.23%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for SCLX and NVO.
Loading charts...
Drawdown Indicators
| SCLX | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.23% | -74.70% | -24.53% |
Max Drawdown (1Y)Largest decline over 1 year | -80.27% | -49.17% | -31.10% |
Max Drawdown (3Y)Largest decline over 3 years | -98.20% | -74.70% | -23.50% |
Max Drawdown (5Y)Largest decline over 5 years | -99.23% | -74.70% | -24.53% |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -97.80% | -65.07% | -32.73% |
Average DrawdownAverage peak-to-trough decline | -57.20% | -17.83% | -39.37% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.80% | 31.04% | +23.76% |
Volatility
SCLX vs. NVO - Volatility Comparison
Scilex Holding Company (SCLX) has a higher volatility of 44.54% compared to Novo Nordisk A/S (NVO) at 11.82%. This indicates that SCLX's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SCLX | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 44.54% | 11.82% | +32.72% |
Volatility (6M)Calculated over the trailing 6-month period | 74.94% | 37.76% | +37.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 124.72% | 51.56% | +73.16% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 112.50% | 38.46% | +74.04% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 109.12% | 32.57% | +76.55% |
Dividends
SCLX vs. NVO - Dividend Comparison
SCLX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.75%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 3.75% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
SCLX Scilex Holding Company | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
SCLX vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Scilex Holding Company and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
SCLX and NVO have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SCLX has higher volatility (44.54%) compared to NVO (11.82%). In terms of maximum drawdown, SCLX dropped -99.23% vs NVO's -74.70%.
SCLX currently has the higher Sharpe Ratio (0.93 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SCLX and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer